（文章来源：证券日报） 证券日报网讯 12月1日晚间，泰坦科技发布公告称，因内部管理需要，公司于近日对主要办公地址进行 了调整，变更后主要办公地址为上海市奉贤区环城西路3111弄258号，邮政编码201402。 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-046 上海泰坦科技股份有限公司 关于变更主要办公地址的公告 公司网址：https://www.titansci.com/ 投资者邮箱：contact@titansci.com 投资者热线：021-60878330 公司传真：021-60878355 联系地址：上海市奉贤区环城西路 3111 弄 258 号 邮政编码：201402 以上变动敬请广大投资者留意，由此给广大投资者带来的不便，敬请谅解！ 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称"公司"）因内部管理需要，于近日 对主要办公地址进行了调整，为方便投资者与公司沟通和交流，现将公司主要办 公地址和投资者联系方式相关情况公告如下： 二、公司最新联系方式 公司除主要办公地址变更外，投资者热线等联系方式未发生变化，具体联系 方式如下： 上海泰坦科技股份有限公司董事会 2025 年 12 月 2 日 1 一、公司联系方式变更情况 联系方式 变更前 变更后 主要办 ...

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of December 1, Titan Technology's stock price increased by 2.14%, reaching 23.40 yuan per share, with a total market capitalization of 3.848 billion yuan [1] - Year-to-date, the stock price has risen by 28.78%, with a 4.09% increase over the last five trading days, a 4.29% decrease over the last 20 days, and a 10.52% decrease over the last 60 days [1] - The stock has a turnover rate of 0.70%, with a trading volume of 26.5661 million yuan [1] Shareholder Information - As of September 30, the number of shareholders increased by 20.41% to 9,293, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segments - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1]

Core Points - The company has issued its first phase of technology innovation bonds for 2025, with a total issuance amount of 50 million RMB [2] - The bonds have a maturity of 365 days and an interest rate of 3.19% [2] - The funds raised will be used to optimize the company's debt structure, broaden financing channels, and reduce financial costs, while also supporting national technology innovation policies [2] Summary by Sections - **Bond Issuance Details** - The company has completed the issuance of the 2025 first phase technology innovation bonds, with an issuance amount of 50 million RMB [2] - The bonds have a face value of 100 RMB and are organized by Shanghai Rural Commercial Bank as the lead underwriter [2] - **Purpose of Fundraising** - The raised funds will be utilized to optimize the company's debt structure and expand financing channels [2] - The company aims to lower financial costs and increase investment in technology innovation in response to national policies [2]

证券日报网讯 11月28日晚间，泰坦科技发布公告称，公司已于近日完成了上海泰坦科技股份有限公司 2025年度第一期科技创新债券[债券简称：25泰坦科技CP001（科创债）]的发行。本期债券发行额为5， 000.00万元人民币，期限为365日，债券面值为人民币100.00元，发行利率为3.19%。 （文章来源：证券日报） ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-045 2025 年 11 月 29 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称公司）于2025年8月20日召开第四届 董事会第十八次会议，于2025年9月5日召开2025年度第一次临时股东大会，审议 通过了《关于公司拟申请注册发行短期融资券的议案》。根据公司战略发展规划 及资金需求，公司拟向中国银行间市场交易商协会申请注册发行规模不超过1亿 元（含1亿元）的短期融资券（即科技创新债券）。具体内容详见公司于2025年8 月21日在指定媒体披露的《上海泰坦科技股份有限公司关于公司拟申请注册发行 短期融资券的公告》（公告编号：2025-030）。 公司已于近日完成了上海泰坦科技股份有限公司2025年度第一期科技创新 债券[债券简称：25泰坦科技CP001（科创债）]的发行。本期债券发行额为5,000.00 万元人民币，期限为365日，债券面值为人民币100.00元，发行利率为3.19%。本 期债券由上海农村商业银行股 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-044 上海泰坦科技股份有限公司 关于公司与关联方共同投资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 上海泰坦科技股份有限公司（以下简称"泰坦科技"或"上市公司"或"公司"）和关联方上海泰坦合源一期 私募投资基金合伙企业（有限合伙）（以下简称"一期基金"）拟共同投资，对泰坦科技控股子公司上海 泰坦微源检测技术有限公司（以下简称"标的"或"微源检测"）进行增资。增资前，微源检测注册资本为 1000万元，泰坦科技100%持股；增资后，微源检测注册资本为5000万元，其中泰坦科技持股70%，一 期基金持股30%。微源检测新增的4000万元注册资本，泰坦科技认缴2500万元，一期基金认缴1500万 元，泰坦科技资金来源为自有资金。 ● 风险提示： 微源检测目前尚未开展业务，在未来的经营过程中，标的可能会面临行业变化、市场竞争、经营管理以 及不可抗力等风险，公司本次投资的收益具有不确定性，可能面临投资失败或者不达预期等情形。请各 位投 ...

Core Viewpoint - Titan Technology announced a joint investment with its affiliate, Shanghai Titan He Yuan Phase I Private Investment Fund Partnership (Limited Partnership), to increase capital in its subsidiary, Shanghai Titan Micro Source Testing Technology Co., Ltd. [1] Group 1: Investment Details - The current registered capital of Micro Source Testing is 10 million yuan, fully owned by Titan Technology [1] - After the capital increase, the registered capital will rise to 50 million yuan, with Titan Technology holding 70% and the Phase I Fund holding 30% [1] - The additional 40 million yuan in registered capital will be contributed by Titan Technology (25 million yuan) and the Phase I Fund (15 million yuan), with Titan Technology using its own funds for this investment [1] Group 2: Transaction Nature - This investment is classified as a related party transaction due to the involvement of an affiliate [1]

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

证券代码：688133 证券简称：泰坦科技 公告编号：2025-044 上海泰坦科技股份有限公司 关于公司与关联方共同投资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 上海泰坦科技股份有限公司（以下简称"泰坦科技"或"上市公司"或"公 司"）和关联方上海泰坦合源一期私募投资基金合伙企业（有限合伙）（以下简 称"一期基金"）拟共同投资，对泰坦科技控股子公司上海泰坦微源检测技术有 限公司（以下简称"标的"或"微源检测"）进行增资。增资前，微源检测注册 资本为 1000 万元，泰坦科技 100%持股；增资后，微源检测注册资本为 5000 万元， 其中泰坦科技持股 70%，一期基金持股 30%。微源检测新增的 4000 万元注册资本， 泰坦科技认缴 2500 万元，一期基金认缴 1500 万元，泰坦科技资金来源为自有资 金。 本次投资系与关联方共同投资，构成关联交易，但不构成《上市公司重 大资产重组管理办法》规定的重大资产重组，交易实施亦不存在重大法律障碍。 至本次关联交易为止，过去 12 个月内 ...